


See and Hear What the Field Is Discussing!

Psychiatric Services features research related to the delivery of mental health services, especially for people with serious mental illness in community-based treatment programs. Provision of high-quality care involves collaboration among a variety of professionals. Clinicians, administrators, and policy makers look to *Psychiatric Services* for research on how to deliver evidence-based treatments, to take an integrated “whole-health” approach to care, and to better engage individuals in their care. Mental health’s current focus on patient-centered, recovery-oriented care and on dissemination of evidence-based practices is transforming service delivery systems at all levels. Research published in *Psychiatric Services* contributes to this transformation.



Our Most Talked About Articles this year:



Attention-Deficit Hyperactivity Disorder Stimulant Therapy and Prescription Drug Misuse During Transition to Young Adulthood

Published online Feb. 7, 2024



Personal Recovery Among People at Risk for Developing Serious Mental Health Problems: A Qualitative Systematic Review

Published online Feb. 27, 2024

The Discussion Continues: *Psychiatric Services*' Podcast “From Pages to Practice”

Editor Lisa Dixon, M.D., M.P.H., and Podcast Editor and co-host Josh Berezin, M.D., M.S., discuss the latest mental health services research published in *Psychiatric Services* and why it is relevant. Topics include community-based treatment programs, collaborative care, evidence-based treatment and service delivery, criminal and social justice, policy analysis, and more. Recent episodes include:



Predicting Outcomes of Antidepressant Treatment in Community Practice Settings

Gregory E. Simon, M.D., M.P.H., discusses the use of machine-learning models to analyze electronic health records to predict antidepressant treatment response.

Remodeling Broken Systems: Addressing the National Emergency in Child and Adolescent Mental Health

Misty C. Richards, M.D., M.S., and Nicole Kozloff, M.D., discuss the need to remodel our systems and provision of mental health services for children and adolescents.

Brief Summary: for full Prescribing Information and Patient Information, refer to package insert.

INDICATIONS AND USAGE

INGREZZA® (valbenazine) capsules is indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease.

WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON'S DISEASE

VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington's disease. Anyone considering the use of INGREZZA must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician.

Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington's disease.

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS AND PRECAUTIONS

Depression and Suicidal Ideation and Behavior in Patients with Huntington's Disease

Patients with Huntington's disease are at increased risk for depression, and suicidal ideation or behaviors. VMAT2 inhibitors, including INGREZZA, can increase the risk for suicidal ideation and behaviors in patients with Huntington's disease.

In a 14-week, double-blind, placebo-controlled trial, depression or depressed mood was reported in 4.7% of patients taking INGREZZA compared to 1.6% of patients who received placebo, and no patients taking INGREZZA reported suicidal ideation or behavior compared to 1 patient (1.6%) who received placebo. Patients with significant risk for suicidal behavior or with unstable psychiatric symptoms were excluded from this trial. Suicidal ideation (9 subjects; 7.2%) and suicide attempts (3 subjects; 2.4%) were reported in the longer open-label extension trial (N = 125).

When considering the use of INGREZZA, the risk of suicidal ideation and behaviors must be balanced against the need for treatment of chorea. All patients treated with INGREZZA should be observed for new or worsening depression, suicidal ideation or behaviors. If any of these reactions occur and do not resolve, consider discontinuing treatment with INGREZZA.

Hypersensitivity Reactions

Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in the post-marketing setting in patients after taking the first or subsequent doses of INGREZZA. A case of angioedema involving the lips and face, with rash and shortness of breath was reported in a patient with Huntington's disease taking INGREZZA during a clinical study. Urticaria and rash were also reported during a clinical study in patients with Huntington's disease. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA.

Somnolence and Sedation

INGREZZA can cause somnolence and sedation, which was the most common adverse reaction in placebo-controlled trials. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA concentrations may be higher and QT prolongation clinically significant. For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. For patients taking a strong CYP3A4 inhibitor, reduce the dose of INGREZZA to 40 mg once daily. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Neuroleptic Malignant Syndrome (NMS)

A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. In the post-marketing setting, NMS has been reported in patients taking VMAT2 inhibitors, including INGREZZA. Clinicians should be alerted to the signs and symptoms associated with NMS. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria, rhabdomyolysis, and acute renal failure. The diagnosis of NMS can be complicated; other serious medical illness (e.g., pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal disorders can present with similar signs and symptoms. Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include (1) immediate discontinuation of INGREZZA; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.

Recurrence of NMS has been reported with resumption of drug therapy. If treatment with INGREZZA is needed after recovery from NMS, patients should be monitored for signs of recurrence.

Parkinsonism

INGREZZA may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. In the 3 placebo-controlled clinical studies in patients with tardive dyskinesia, the incidence of parkinson-like adverse events was 3% of patients treated with INGREZZA and <1% of placebo-treated patients.

In a placebo-controlled clinical study in patients with chorea associated with Huntington's disease, the incidence of parkinson-like adverse events was 4.7% in patients treated with INGREZZA and 0% in placebo-treated patients. Because rigidity can develop as part of the underlying disease process in Huntington's disease, it may be difficult to distinguish between potential drug-induced parkinsonism and progression of underlying Huntington's disease. Drug-induced parkinsonism has the potential to cause more functional disability than untreated chorea for some patients with Huntington's disease.

Postmarketing safety reports have described parkinson-like symptoms in patients taking INGREZZA for tardive dyskinesia, some of which were severe and required hospitalization. In most cases, severe parkinsonism occurred within the first 2 weeks after starting or increasing the dose of INGREZZA. Associated symptoms have included falls, gait disturbances, tremor, drooling and hypokinesia. In cases in which follow-up clinical information was available, parkinson-like symptoms were reported to resolve following discontinuation of INGREZZA therapy. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling:

- Depression and Suicidal Ideation and Behavior in Patients with Huntington's Disease
- Hypersensitivity Reactions
- Somnolence and Sedation
- QT Prolongation
- Neuroleptic Malignant Syndrome (NMS)
- Parkinsonism

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Tardive Dyskinesia

Variable and Fixed Dose Placebo-Controlled Trial Experience

The safety of INGREZZA was evaluated in 3 placebo-controlled studies, each 6 weeks in duration (fixed dose, dose escalation, dose reduction), including 445 patients. Patients were 26 to 84 years of age with moderate to severe tardive dyskinesia and had concurrent diagnoses of mood disorder (27%) or schizophrenia/schizoaffective disorder (72%). The mean age was 56 years. Patients were 57% Caucasian, 39% African-American, and 4% other. With respect to ethnicity, 28% were Hispanic or Latino. All subjects continued previous stable regimens of antipsychotics; 85% and 27% of subjects, respectively, were taking atypical and typical antipsychotic medications at study entry.

Adverse Reactions Leading to Discontinuation of Treatment

A total of 3% of INGREZZA-treated patients and 2% of placebo-treated patients discontinued because of adverse reactions.

Common Adverse Reactions

Adverse reactions that occurred in the 3 placebo-controlled studies at an incidence of $\geq 2\%$ and greater than placebo are presented in Table 1.

Table 1: Adverse Reactions in 3 Placebo-Controlled Studies of 6-week Treatment Duration Reported at $\geq 2\%$ and >Placebo – Tardive Dyskinesia

| Adverse Reaction ¹ | INGREZZA (n=262) % | Placebo (n=183) % |
|----------------------------------------------------------------------------------------------------------------|--------------------|-------------------|
| General Disorders | | |
| Somnolence (somnolence, fatigue, sedation) | 10.9 | 4.2 |
| Nervous System Disorders | | |
| Anticholinergic effects (dry mouth, constipation, disturbance in attention, vision blurred, urinary retention) | 5.4 | 4.9 |
| Balance disorders/fall (fall, gait disturbance, dizziness, balance disorder) | 4.1 | 2.2 |
| Headache | 3.4 | 2.7 |
| Akathisia (akathisia, restlessness) | 2.7 | 0.5 |
| Gastrointestinal Disorders | | |
| Vomiting | 2.6 | 0.6 |
| Nausea | 2.3 | 2.1 |
| Musculoskeletal Disorders | | |
| Arthralgia | 2.3 | 0.5 |

¹Within each adverse reaction category, the observed adverse reactions are listed in order of decreasing frequency.

Other Adverse Reactions Observed During the Premarketing Evaluation of INGREZZA

Other adverse reactions of $\geq 1\%$ incidence and greater than placebo are shown below. The following list does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo.

Endocrine Disorders: blood glucose increased

General Disorders: weight increased

Infectious Disorders: respiratory infections

Neurologic Disorders: drooling, dyskinesia, extrapyramidal symptoms (non-akathisia)

Psychiatric Disorders: anxiety, insomnia

During the tardive dyskinesia controlled trials, there was a dose-related increase in prolactin. Additionally, in these trials there was a dose-related increase in alkaline phosphatase and bilirubin, suggesting a potential risk for cholestasis.

Chorea Associated with Huntington's Disease

The safety of INGREZZA was evaluated in a 14-week placebo-controlled study including 127 patients with chorea associated with Huntington's disease. Patients were 25 to 75 years of age. The mean age was 54 years. Patients were 96% Caucasian, 1% African-American, 1% Asian, and 2% Other. With respect to ethnicity, 6% were Hispanic or Latino.

Adverse Reactions Leading to Discontinuation of Treatment

A total of 8% of INGREZZA-treated patients and 6% of placebo-treated patients discontinued because of adverse reactions.

Common Adverse Reactions

Adverse reactions that occurred in the placebo-controlled study at an incidence of $\geq 4\%$ and greater than placebo are presented in Table 2.

Table 2: Adverse Reactions in the Placebo-Controlled Study of 12-week Treatment Duration Reported at $\geq 4\%$ and $>$ Placebo – Chorea Associated with Huntington's Disease

| Adverse Reaction | INGREZZA (n=64) % | Placebo (n=63) % |
|-------------------------------------------------------------|-------------------|------------------|
| Nervous System Disorders | | |
| Somnolence, lethargy, sedation | 18.8 | 3.2 |
| Akathisia | 6.3 | 4.8 |
| General Disorders and Administration Site Conditions | | |
| Fatigue | 14.1 | 9.5 |
| Skin and Subcutaneous Tissue Disorders | | |
| Urticaria | 9.4 | 0 |
| Rash | 7.8 | 0 |
| Gastrointestinal Disorders | | |
| Diarrhea | 4.7 | 1.6 |
| Nausea | 4.7 | 0 |
| Psychiatric Disorders | | |
| Insomnia, middle insomnia | 6.3 | 1.6 |
| Depression, depressed mood | 4.7 | 1.6 |
| Musculoskeletal Disorders | | |
| Back pain | 4.7 | 0 |

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of INGREZZA that are not included in other sections of labeling. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: hypersensitivity reactions (including allergic dermatitis, and pruritus)

DRUG INTERACTIONS

Drugs Having Clinically Important Interactions with INGREZZA

Table 3: Clinically Significant Drug Interactions with INGREZZA

| Monoamine Oxidase Inhibitors (MAOIs) | |
|---------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Clinical Implication:</i> | Concomitant use of INGREZZA with MAOIs may increase the concentration of monoamine neurotransmitters in synapses, potentially leading to increased risk of adverse reactions such as serotonin syndrome, or attenuated treatment effect of INGREZZA. |
| <i>Prevention or Management:</i> | Avoid concomitant use of INGREZZA with MAOIs, or within 14 days of discontinuing therapy with an MAOI. |
| Strong CYP3A4 Inhibitors | |
| <i>Clinical Implication:</i> | Concomitant use of INGREZZA with strong CYP3A4 inhibitors increased the exposure (C _{max} and AUC) to valbenazine's active metabolite compared with the use of INGREZZA alone. Increased exposure of valbenazine and its active metabolite may increase the risk of exposure-related adverse reactions. |
| <i>Prevention or Management:</i> | Reduce INGREZZA dose when INGREZZA is coadministered with a strong CYP3A4 inhibitor. |
| Strong CYP2D6 Inhibitors | |
| <i>Clinical Implication:</i> | Concomitant use of INGREZZA with strong CYP2D6 inhibitors increased the exposure (C _{max} and AUC) to valbenazine's active metabolite compared with the use of INGREZZA alone. Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions. |
| <i>Prevention or Management:</i> | Reduce INGREZZA dose when INGREZZA is coadministered with a strong CYP2D6 inhibitor. |
| Strong CYP3A4 Inducers | |
| <i>Clinical Implication:</i> | Concomitant use of INGREZZA with a strong CYP3A4 inducer decreased the exposure of valbenazine and its active metabolite compared to the use of INGREZZA alone. Reduced exposure of valbenazine and its active metabolite may reduce efficacy. |
| <i>Prevention or Management:</i> | Concomitant use of strong CYP3A4 inducers with INGREZZA is not recommended. |
| Digoxin | |
| <i>Clinical Implication:</i> | Concomitant use of INGREZZA with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp). |
| <i>Prevention or Management:</i> | Digoxin concentrations should be monitored when co-administering INGREZZA with digoxin. Increased digoxin exposure may increase the risk of exposure-related adverse reactions. Dosage adjustment of digoxin may be necessary. |

OVERDOSAGE

Human Experience

The pre-marketing clinical trials involving INGREZZA in approximately 850 subjects do not provide information regarding symptoms with overdose.

Management of Overdosage

No specific antidotes for INGREZZA are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a Certified Poison Control Center (1-800-222-1222 or www.poisson.org).

For further information on INGREZZA, call 84-INGREZZA (844-647-3992).



Distributed by:
Neurocrine Biosciences, Inc.
San Diego, CA 92130

INGREZZA is a registered trademark of Neurocrine Biosciences, Inc.
CP-VBZ-US-2810 08/2023

FOR YOUR ADULT PATIENTS WITH TARDIVE DYSKINESIA (TD)

ADVERTISEMENT

ONCE-DAILY
INGREZZA[®]
(valbenazine) capsules

Control.

Actor portrayal

Made simple.

INGREZZA is the only one-capsule, once-daily choice proven to reduce TD severity¹

UNIQUELY SELECTIVE

Only INGREZZA exclusively delivers **one primary metabolite** (+ α) for potent and selective inhibition of VMAT2^{1,3,*}

PROVEN EFFICACY

INGREZZA 80 mg reduced uncontrolled movements in **7 of 10 patients at 6 weeks** (post hoc analysis)^{14,†}

SIMPLE FROM THE START

The only VMAT2 inhibitor that offers an **effective starting dosage** you can adjust based on response and tolerability¹

SAVINGS & SUPPORT

\$10 or less out-of-pocket is what most patients pay for INGREZZA⁵

*Based on *in vitro* VMAT2 binding affinity of dihydrotetraabenazine (HTBZ) metabolites and INGREZZA's primary active metabolite, + α HTBZ. The clinical significance of *in vitro* data is unknown and is not meant to imply clinical outcomes.

†Post hoc analysis included patients who had a baseline and a Week 6 AIMS total score. Reduction in uncontrolled movements as assessed by ≥ 1 -point decrease in AIMS total score.



Visit [INGREZZAHCP.com/Results](https://www.ingrezzahcp.com/results) to see how you can help your TD patients take control



Important Information

INDICATION & USAGE

INGREZZA[®] (valbenazine) capsules is indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington's Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington's disease.

CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA.

WARNINGS & PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in patients after taking the first or subsequent doses of INGREZZA. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA.

Somnolence and Sedation

INGREZZA can cause somnolence and sedation. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

WARNINGS & PRECAUTIONS (continued)

Neuroleptic Malignant Syndrome

A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission, including INGREZZA. The management of NMS should include immediate discontinuation of INGREZZA, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems. If treatment with INGREZZA is needed after recovery from NMS, patients should be monitored for signs of recurrence.

Parkinsonism

INGREZZA may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS

The most common adverse reaction in patients with tardive dyskinesia ($\geq 5\%$ and twice the rate of placebo) is somnolence.

The most common adverse reactions in patients with Huntington's disease ($>5\%$ and twice the rate of placebo) are somnolence/lethargy/sedation, urticaria, rash, and insomnia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the adjacent pages for Brief Summary of Prescribing Information and visit Neurocrine.com/INGREZZAPI for full Prescribing Information, including Boxed Warning.

REFERENCES: 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc. 2. Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE. VMAT2 inhibitors and the path to INGREZZA (valbenazine). *Prog Med Chem.* 2018;57(1):87-111. 3. Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. *J Pharmacol Exp Ther.* 2017;361(3):454-461. 4. Data on file. Neurocrine Biosciences, Inc. 5. Measured by NDC; data on file as of Q2 2023. Neurocrine Biosciences, Inc. 6. Data on file as of Q4 2022. Neurocrine Biosciences, Inc.



©2024 Neurocrine Biosciences Inc. All Rights Reserved.
CP-VBZ-US-3125 03/2024